Fat stem cells and light may restore skin color in vitiligo
NCT ID NCT07690501
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study tests whether injecting a person's own fat-derived stem cells into stable vitiligo patches, alone or combined with excimer light therapy, can safely bring back skin color. Fifteen adults with stable vitiligo patches will receive the treatment. The goal is to see if the stem cells and light can stop disease activity and promote repigmentation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Adipose-derived stem cells
- What this could lead to
- If successful, this approach could offer a new way to restore skin color in people with stable vitiligo.
- What could go wrong
- This is a very small, early-stage study with only 15 participants. Results may not apply to everyone, and the treatment may not work or could cause side effects like infection or poor donor site healing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Aug 2023
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 to 52 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least. * Patients who will accept to be enrolled in the study and will sign an informed consent. Exclusion Criteria: * Unstable vitiligo for more than 6 months. * Current bacterial or viral infection in the treatment area. * Patients with unrealistic expectation. * Very thin patients "poor donor areas". * Patients with uncontrolled systemic disease such as diabetes or hypertension. * Patients with hepatitis B or C virus infection. * Patients with any other skin disease. * Patients with bleeding or coagulopathy disorders. * Pregnancy and lactation. * Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adipose-derived stem cells are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, El-Gharbia, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.